Similarly, for PARP inhibitors, much of the focus in prostate cancer has been on the “synthetic lethality” mechanism, which has resulted in these agents becoming available for the treatment of patients with BRCA1/2 or ATM-loss prostate cancer [18]. The gene discussed is PARP1; the disease is prostate carcinoma.